Patents by Inventor Boris Schwartsburd

Boris Schwartsburd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
    Patent number: 11850275
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: December 26, 2023
    Assignee: 89bio, Inc.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES
    Publication number: 20230338471
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Application
    Filed: February 6, 2023
    Publication date: October 26, 2023
    Applicant: 89BIO, INC.
    Inventors: Boris SCHWARTSBURD, Shaji JOSEPH
  • Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
    Patent number: 11596669
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: March 7, 2023
    Assignee: 89BIO, INC.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES
    Publication number: 20220296678
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 22, 2022
    Applicant: 89Bio, Inc.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • INTERLEUKIN-18 BINDING PROTEINS, THEIR PREPARATION AND USE FOR THE TREATMENT OF SEPSIS
    Publication number: 20100254941
    Abstract: The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction.
    Type: Application
    Filed: March 1, 2010
    Publication date: October 7, 2010
    Applicant: Yeda Research Institute and Development Ltd.
    Inventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim, Giamila Fantuzzi, Leonid L. Reznikov, Boris Schwartsburd
  • Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
    Patent number: 7704944
    Abstract: The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: April 27, 2010
    Assignee: Yeda Research and Development Company Ltd.
    Inventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim, Giamila Fantuzzi, Leonid L. Reznikov, Boris Schwartsburd
  • Method for the purification of a non-immunoglobulin protein comprising an immunoglobulin-like (Ig-like) domain
    Patent number: 7550563
    Abstract: The present invention relates to a method for the purification of non-immunoglobulin proteins comprising one or more immunoglobulin-like (Ig-like) domain.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: June 23, 2009
    Assignee: Laboratoires Serono SA
    Inventors: Boris Schwartsburd, Ilana Belzer
  • Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
    Publication number: 20070081975
    Abstract: The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction.
    Type: Application
    Filed: August 16, 2006
    Publication date: April 12, 2007
    Inventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Kim, Giamila Fantuzzi, Leonid Reznikov, Boris Schwartsburd
  • Method for the purification of a non-immunoglobulin protein comprising an immunoglobulin-like (ig-like) domain
    Publication number: 20070032638
    Abstract: The present invention relates to a method for the purification of non-immunoglobulin proteins comprising one or more immunoglobulin-like (Ig-like) domain.
    Type: Application
    Filed: August 5, 2004
    Publication date: February 8, 2007
    Applicant: Applied Research Systems ARS Holding N.V.
    Inventors: Boris Schwartsburd, Ilana Belzer
  • Method and kit for quantitation of polypeptides
    Publication number: 20040203077
    Abstract: The invention relates to a method for quantitation of recombinant proteins of interest in the absence of specific antibodies, which is particularly suitable for screening cell clones expressing heterologous genes.
    Type: Application
    Filed: May 4, 2004
    Publication date: October 14, 2004
    Applicant: APPLIED RESEARCH SYSTEMS ARD HOLDING N. V.
    Inventor: Boris Schwartsburd
  • Use of IL-18 inhibitors for the treatment or prevention of sepsis
    Publication number: 20030008822
    Abstract: The present invention provides a method of treatment and/or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrone (SIRS), including severe sepsis, septic shock and sepsis related to cardiac dysfunction.
    Type: Application
    Filed: May 16, 2002
    Publication date: January 9, 2003
    Inventors: Charles Dinarello, Soo-Hyun Kim, Giamila Fantuzzi, Leonid L. Reznikov, Menahem Rubinstein, Daniela Novick, Boris Schwartsburd